“This novel regimen of pazopanib alternating with bevacizumab was found to be safe and efficacious in untreated patients with ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding bevacizumab to first-line chemotherapy for patients with ovarian cancer, ...

At current standard of care, less than half of women with recurrent platinum sensitive ovarian cancer who have had prior treatment with poly(ADP-ribose) polymerase inhibitors respond to subsequent ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

A retrospective single-center cohort of 128 patients associated frontline bevacizumab with longer overall survival in ...

National Institute for Health and Care Excellence (NICE) has recommended Lonsurf (trifluridine–tipiracil, Servier Laboratories) plus bevacizumab in final draft guidance for treating metastatic ...

The Phase 1 study by Lilly assessed Sofe-M plus bevacizumab in 33 women with platinum-sensitive ovarian cancer (PSOC).

Ovarian cancer comprises a group of different cancers that can form in the ovaries, fallopian tubes, or the peritoneum. For those patients within this population with aggressive disease, continuous ...

November 18, 2011 — The US Food and Drug Administration (FDA) announced today that it is rescinding its approval of bevacizumab (Avastin, Genentech) for treating metastatic breast cancer because the ...

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies ...